9,850 Shares in Zoetis Inc. $ZTS Bought by Twin Tree Management LP

Twin Tree Management LP bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,850 shares of the company’s stock, valued at approximately $1,239,000.

Several other institutional investors have also recently made changes to their positions in ZTS. Norges Bank purchased a new position in shares of Zoetis during the fourth quarter worth $734,425,000. Vanguard Group Inc. raised its holdings in shares of Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Montrusco Bolton Investments Inc. raised its holdings in shares of Zoetis by 256.7% during the fourth quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock worth $266,888,000 after purchasing an additional 1,560,314 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock worth $394,746,000 after acquiring an additional 1,227,085 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In related news, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by insiders.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis received UK approval for Lenivia (izenivetmab), a long-acting osteoarthritis pain therapy for dogs, which could support future product sales and help offset some legal-related negativity. Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia
• Neutral Sentiment: Multiple law firms, including Rosen Law Firm, Levi & Korsinsky, Glancy Prongay Wolke & Rotter, Robbins Geller, the Schall Law Firm, Bronstein Gewirtz & Grossman, and DJS Law Group, issued repeated reminders about the pending securities class action and the July 27 lead-plaintiff deadline. ROSEN, A LONGSTANDING LAW FIRM, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
• Negative Sentiment: The class-action filings alleging securities-law violations and investor losses may increase legal costs, create headline risk, and keep pressure on Zoetis shares until more clarity emerges. Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ZTS shares. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. UBS Group cut their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Morgan Stanley restated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research note on Friday, May 15th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, Stifel Nicolaus cut their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Friday, May 22nd. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $133.92.

Zoetis Stock Performance

ZTS opened at $78.80 on Tuesday. The firm has a market capitalization of $33.03 billion, a PE ratio of 13.07, a PEG ratio of 1.24 and a beta of 0.75. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $169.50. The firm’s 50-day moving average price is $99.76 and its 200 day moving average price is $115.24. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.